Navigation Links
23andMe scientists receive approximately $1.4 million in funding from National Institutes of Health
Date:7/29/2014

23andMe, the leading personal genetics company, has received from the National Institutes of Health (NIH) a grant totaling $1,367,504 for a two-year project to support the further development of 23andMe's web-based database and research engine for genetic discovery.

Specifically, the grant supports four areas of development:

  • Refinement of web-based surveys to improve the company's ability to identify novel genetic associations;
  • Enhanced infrastructure of survey tools to support the collection of a broader set of phenotypic data;
  • The utilization of whole-genome sequencing data and imputation to enable the discovery of rarer, more penetrant genetic associations; and
  • Enablement of external non-23andMe researchers to access aggregate de-identified data from the 23andMe database to further accelerate the pace of human genetic research.

"23andMe is building a platform to connect researchers and consumers that will enable discoveries to happen faster," said Anne Wojcicki, co-founder and CEO of 23andMe. "This grant from the NIH recognizes the ability of 23andMe to create a unique, web-based platform that engages consumers and enables researchers from around the world to make genetic discoveries."

The grant will enable 23andMe to refine current survey questions, release 15 new questionnaires, and discover novel associations between health conditions and genetic variants. The company will publish new discoveries in peer-reviewed scientific journals.

The grant also supports improvements to survey infrastructure and the creation of new tools for collection of phenotypic data. This will improve the usability of surveys, including an updatable health profile where participants can keep track of known health conditions and add simple interactive cognitive tests to the 23andMe website.

The grant also supports 23andMe's efforts to utilize available whole-genome sequence data and imputation in order to discover rare variants associated with disease. 23andMe will impute genotypes using data from large public and internal sequencing projects, thus providing increased power to detect many novel associations, including rare variants with large effects. This type of analysis represents a model for how previous investments in genome-wide association studies will be utilized in the next generation of genetics research.

The grant's final area of support is the company's efforts to collaborate with academic and commercial partners to test and refine the Research Accelerator. The Research Accelerator provides access to aggregate de-identified genotype and phenotype data from 23andMe customers who have consented to participate in the company's research program. 23andMe will give a limited set of partners early access to the Research Accelerator and will create reports and tools so that partners are able to see which single nucleotide polymorphisms (SNPs) are associated with conditions of interest; to find conditions associated with variants in individual genes; and to view other aggregate data. By providing access to the de-identified aggregate data, individual-level information remains protected while researchers from around the world have an opportunity to use genetic and phenotypic data from 23andMe to make discoveries.

Overall, this project will yield a database containing genotypes for 40 million SNPs and information on thousands of diseases and traits for more than 400,000 individuals. Novel associations, especially with the rare genetic variants imputed by 23andMe, will be of great value for disease prediction, drug development, and biological understanding.

23andMe now has more than 700,000 genotyped customers and more than 80 percent actively participate in the company's research surveys. The company has collected nearly 200 million individual survey responses to date. 23andMe has published 16 papers in peer-reviewed scientific journals over the past three years.

The specific projects described are supported by NIH Award 2R44HG006981-02 from the National Human Genome Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Human Genome Research Institute, or the National Institutes of Health.


'/>"/>

Contact: Catherine Afarian
cafarian@23andme.com
23andMe Inc.
Source:Eurekalert

Related biology news :

1. 23andMe helps identify 11 new genetic associations for asthma-with-hay fever
2. 23andMe conducts the first genetic study of non-syndromic striae distensae (stretch marks)
3. 23andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies
4. 23andMe identifies multiple genetic factors impacting development of nearsightedness
5. 23andMes Ancestry Composition reveals peoples ancestral origins going back 500+ years
6. 23andMe scientists receive more than $500,000 in National Institutes of Health funding
7. 23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership Positions
8. 23andMe opens its API to developers
9. 23andMe contributes to genetic discoveries related to male pattern baldness
10. 23andMe identifies 5 significant genetic associations for hypothyroidism
11. Scientists discover genetic switch that can prevent peripheral vascular disease in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... HANOVER, Germany , March 20, 2017 At ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the ... Japan is this year,s CeBIT partner country. At the largest ... important biometrics in use: fingerprint, face and iris recognition as well as ... ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
(Date:3/7/2017)... -- Brandwatch , the leading social intelligence company, today announces ... to uncover insights to support its reporting, help direct future campaigns, ... leading youth charity will be using Brandwatch Analytics social listening and ... understanding of the topics and issues that are a priority for ... "Until ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... MA (PRWEB) , ... March ... ... Group ( WMFTG ) has unveiled its innovative Quantum peristaltic pump with ... peristaltic innovation, Quantum sets the new standard for high-pressure feed pumps in ...
(Date:3/22/2017)... , March 22, 2017  Personal Genome ... its cancer testing contract with the U.S. Department ... tumor profiling assay with the company,s new CancerSELECT ... comprehensive, clinically actionable pan-cancer profiling test that includes ... assess potential patient response to checkpoint inhibitor immunotherapies. ...
(Date:3/20/2017)... ... March 20, 2017 , ... HOLLOWAY AMERICA, ... recently announced it will debut a brand new pressure vessel, the intelliVesselâ„¢, at ... controlled by a touch screen panel and features other revolutionary operations that promote ...
(Date:3/20/2017)... ... March 20, 2017 , ... Park Systems, a leader in Atomic Force ... March 24, 2017 from 5-7pm at their Santa Clara facility that will include craft ... Senior Researcher, Dr. Tae-Gon Kim. , Dr. Tae-Gon Kim, Senior researcher at imec Belgium ...
Breaking Biology Technology: